NRG-BN002: Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma

Principal Investigator

Mark R. Gilbert, MD

Primary Objective

Determine the maximum safe dose of single-agent treatment with ipilimumab, nivolumab and the combination when given with temozolomide during maintenance treatment for newly diagnosed glioblastoma.

Patient Population

Histopathologically proven diagnosis of glioblastoma or gliosarcoma prior to registration by pathology report. The tumor must be unifocal, confined to the supratentorial compartment and have undergone a gross total or near gross total resection.  
Please note: This is a limited-institution study with pre-selected sites.

Target Accrual

42 patients


Activated April 16, 2015

Protocol Documents

The protocol and related documents will be available at NRG-BN002

NRG-BN002 irAE Training Webinar  
*As there were technical difficulties with the sound at the beginning of the webinar, please begin your review at the 7:55 minute time point. Thank you.

Copyright 2017 by NRG Oncology